lundi 16 novembre 2026
RechercherExplore
Source trace. Via News points to the documents behind its reporting and shows what we drew from each, so you can check any claim. How we source
Source document· November 24, 2025

Lilly to highlight progress across key programs in early and advanced hormone receptor-positive breast cancer at the 2025 San Antonio Breast Cancer Symposium

View original at finance.yahoo.com
Lilly to highlight progress across key programs in early and advanced hormone receptor-positive breast cancer at the 2025 San Antonio Breast Cancer Symposium Updated results from the Phase 3 EMBER-3 trial for Inluriyo™ (imlunestrant) alone and in combination with Verzenio® (abemaciclib) in ER+, HER2– metastatic breast…
Opening lines of the source · short snapshot: read the full document at the original

Ce que nous avons tiré de cette source

The claims Via News extracted from this document. We point to the source; we don't replace it.

  • PIK3CA mutations are present in approximately 40% of HR+/HER2- breast cancers

    80% confidence
  • ESR1 mutations are a key driver in ER+ breast cancer resistance

    80% confidence
  • HR+, HER2- breast cancer is the most common form of breast cancer

    80% confidence
  • Eli Lilly has nearly 150 years of history pioneering discoveries

    80% confidence
  • Verzenio has been authorized in more than 90 countries

    80% confidence
  • At SABCS 2025, Eli Lilly is showcasing new data across their portfolio addressing the three most important biologic targets in HR+ breast cancer: CDK4/6, the estrogen receptor, and PI3K, reflecting continued momentum and commitment to translating biologic conviction into meaningful progress

    80% confidence
Lilly to highlight progress across key programs in early and advanced hormone receptor-positive breast cancer at the 2025 San Antonio Breast Cancer Symposium: Source | Via News | fr.via.news